Wearable Devices Ltd. sets annual meeting for September 26

Wearable Devices Ltd. has announced its upcoming Annual and Special General Meeting of Shareholders, scheduled for September 26, 2024. According to a recent filing with the SEC, the event will be open to shareholders who hold ordinary shares as of the close of business on August 29, 2024.

The notice included in the SEC Form 6-K filing indicates that shareholders will have the opportunity to vote in person or by proxy at the meeting. The specifics of the agenda items to be discussed at the meeting were not disclosed in the filing.

The SEC filing, dated today, states that the information provided will be incorporated by reference into the company's existing registration statements on Form S-8 and Form F-3. These forms are typically used by companies to register securities for employee stock plans and for the registration of securities to be offered to the public, respectively.

Wearable Devices Ltd., based in Yokne'am Illit, Israel, is listed under the computer communications equipment industry in the SEC's standard industrial classification. The company's CEO, Asher Dahan, signed off on the filing.

In other recent news, Can-Fite BioPharma (NYSE:CANF) has been in the spotlight due to several key developments. The biotechnology company received an upgrade to a Buy rating from EF Hutton, with a price target of $10, which was influenced by the potential of its pipeline drugs, Namodenoson and Piclidenoson. Both drugs were assigned a 70% chance of success, reflecting their advanced stages in clinical trials.

Moreover, Can-Fite reported promising results from a clinical study on dogs with osteoarthritis using Piclidenoson. The drug candidate Namodenoson also received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA) for the treatment of advanced liver cancer. This drug is currently undergoing a pivotal Phase III trial.

Adding to the list of advancements, the FDA granted Investigational New Drug clearance for Namodenoson. This clearance enables the inclusion of U.S. patients in an ongoing Phase IIb trial for metabolic dysfunction-associated steatohepatitis.

In a different vein, Can-Fite received a Notice of Allowance from the European Patent Office for its erectile dysfunction (ED) treatment patent, related to the CF602 drug candidate. The company also expanded its agreement with Ewopharma to include marketing rights for Namodenoson in treating pancreatic carcinoma. These recent developments highlight Can-Fite's continued commitment to drug development and clinical trials.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.